Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting

Anatomical surgical resection in the form of lobectomy with systematic nodal dissection remains the primary treatment modality for resectable NSCLC. Postoperatively, these patients are often treated with cisplatin-based adjuvant chemotherapy. Adjuvant chemotherapy treats the micrometastatic disease that is not radiographically visible, prevents distant spread, and thereby improves the cure rate. This rationale is also supported by the fact that...